

OPPI News Update
March 17, 2015
Foreign secy for realism in US-India trade talks
Publication: [Business Standard](#)
Universal Health Insurance in India: A way to go forward *(Opinion article by Munish Kumar Raizada, who practises neo-natal medicine in Chicago)*
Publication: [The Indian Express](#)
Indo-US ties in transition mode, conceptual problems still exist: Foreign Secretary S Jaishankar *(PTI story)*
Publication: [The Economic Times](#)
Similar reports:
Business Standard – [Indo-US ties in transition mode, conceptual problems still exist: Foreign Secretary S Jaishankar](#)
Clinical Establishment Act not realistic: IMA chief
Publication: [The Times of India](#)
'Indian pharma firms must innovate in face of generic drugs slowdown'
Portal: [Zee News](#)
Similar reports:
Business Standard – ['Indian pharma firms must innovate in face of generic drugs slowdown'](#)
Assam to draft new health policy with special focus on poor
Publication: [Business Standard](#)
Providing effective health cover *(Opinion article by Munish Kumar Raizada, who practises neo-natal medicine in Chicago)*
Publication: [The Pioneer](#)
Why prescription drug spending went through the roof in 2014
Publication: [Business Insider](#)
NPPA moots to replicate Gujarat FDCA model of efficient reporting of DPCO violation cases across India
Portal: [Pharmabiz](#)
Pharma meet 2015 held
Publication: [Free Press Journal](#)
A Doctor's Unbelievable Dilemma
Publication: [The New Indian Express](#)
India's GDP will be bigger than Japan, Germany combined in 4 years: IMF
Publication: [The Economic Times](#)
Similar reports:

The Hindu – [India on the right track: IMF chief](#)

Firstpost – [India a bright spot but reform implementation key: IMF's Lagarde tells PM Modi](#)

“Rights-based approach, awareness essential to eradicate TB”

Publication: [The Hindu](#)

Diseases: No focus on prevention

Publication: [The Hans India](#)

Over 12% meds brought into Maharashtra sub-standard, admits Maharashtra government; says action taken

Publication: [DNA](#)

DoP rejects Inventia Healthcare's review application on metformin HCl, gliclazide and pioglitazone tablets

Portal: [Pharmabiz](#)